COMP <GO>
ADCT vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
ADC Therapeutics SA (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ADCT 2
— JNJ 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $1.53 (+2.69%) • MKT CAP: $195.3M
roic
-35.00%
LAST: $273.20 (-0.73%) • MKT CAP: $657.68B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADCT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADCT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.90% | 67.90% | +25.00 | ADCT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 14.90% | 6.00% | +8.90 | ADCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.9 | 59.1 | -5.20 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $195.3M | $657.68B | -$657.48B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADCT REV | JNJ REV | ADCT GROSS % | JNJ GROSS % | ADCT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $81.4M | $94.19B | 92.9% | 67.9% | -$141.4M | $19.70B |
| FY 2024 | $70.8M | $88.82B | 91.6% | 69.1% | -$124.7M | $19.84B |
| FY 2023 | $69.1M | $85.16B | — | — | -$118.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADCT // BETA —
JNJ // BETA 1.08